You will learn and undertake research (for the MSc programme) in the multi-million-pound, state of the art Blizard Building.
The building was designed by leading architect Will Alsop in partnership with Amec with its 9,000m2 providing world-class teaching and research facilities including open-plan laboratories, office space and the 400-seat Perrin Lecture Theatre. You will be based at the Centre for Neuroscience, Surgery and Trauma, whose researchers focus on themes such as neurotrauma, neurodegeneration, neuroimmunology, and neurogastroenterology. The Centre’s themes are closely linked with clinical academic units within Barts Health NHS Trust, with many of its staff actively involved in clinical research, phase 2 and 3 clinical trials. The research themes are designed to create partnerships between basic scientists and clinicians to encourage true translational research.
The programme is hosted by the Blizard Institute, the largest institute of Queen Mary University of London's Faculty of Medicine and Dentistry. Our research and education span broad areas of modern biomedicine, with particular expertise in cell biology, genomics, immunology, neuroscience, primary care, population health and trauma sciences. Our research puts us among the top research institutions in the UK (REF 2014). We work closely with linked NHS hospital trusts which means that the School’s research and teaching is informed by an exceptionally wide-ranging and stimulating clinical environment. Queen Mary University of London is also part of the prestigious Russell Group - a body of leading UK universities dedicated to research and teaching excellence.
Many of the teaching staff on the programme work collaboratively and with colleagues on interdisciplinary research across the School, such as within the Preventive Neurology Unit at the Wolfson Institute of Population Health. This brings together an expert team to carry out revolutionary new research into Dementia, Multiple Sclerosis and Parkinson's Disease. The Unit is exploring whether simple treatments can prevent or delay the onset of these disorders in order to have a meaningful impact on the global burden of neurological disease through prevention.